0001209191-20-045145.txt : 20200805
0001209191-20-045145.hdr.sgml : 20200805
20200805165128
ACCESSION NUMBER: 0001209191-20-045145
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200803
FILED AS OF DATE: 20200805
DATE AS OF CHANGE: 20200805
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sachdev Amit
CENTRAL INDEX KEY: 0001406338
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 201078313
MAIL ADDRESS:
STREET 1: C/O VERTEX PHARMACEUTICALS INCORPORATED
STREET 2: 130 WAVERLY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-08-03
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001406338
Sachdev Amit
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
0
1
0
0
EVP, Chief Patient Officer
Common Stock
2020-08-03
4
M
0
1941
86.52
A
37044
D
Common Stock
2020-08-03
4
S
0
500
276.96
D
36544
D
Common Stock
2020-08-03
4
S
0
690
278.25
D
35854
D
Common Stock
2020-08-03
4
S
0
751
279.18
D
35103
D
Common Stock
882
I
401(k)
Common Stock
14002
I
Held in Trust
Stock Option (Right to Buy)
86.52
2020-08-03
4
M
0
1941
0.00
D
2027-02-02
Common Stock
1941
3884
D
Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $276.96 (range $276.62 to $277.25).
Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $278.25 (range $277.73 to $278.48).
Open market sales reported on this line occurred at a weighted average price of $279.18 (range $278.92 to $279.61).
The option vests in 16 quarterly installments from 02/03/2017.
/s/ Sabrina Yohai, Attorney-in-Fact
2020-08-05